Charles River acquires Retrogenix for $48M

By The Science Advisory Board staff writers

April 1, 2021 -- Charles River Laboratories has paid approximately $48 million U.S. to acquire the U.K.-based contract research organization Retrogenix.

The acquisition strengthens Charles River's expertise with the addition of cell microarray technology and off-target screening for preclinical safety assurance in chimeric antigen receptor (CAR) T-cell therapies. Retrogenix's cell microarray technology can identify specific cell surface and secreted protein interactions in human cells, the firm said.

A potential additional payment of up to $7 million for future performance is included in the deal.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.